Zydus Receives USFDA Approval For ZITUVIMET To Treat Adult Patients With Type 2 Diabetes Mellitus

Zydus Receives USFDA Approval For ZITUVIMET To Treat Adult Patients With Type 2 Diabetes Mellitus

The shares of Zydus Lifesciences Limited on Monday at 9:47 am IST were trading at Rs 587.25, up by 0.41 percent.

FPJ Web DeskUpdated: Monday, November 06, 2023, 09:50 AM IST
article-image
Zydus Receives USFDA Approval For ZITUVIMET To Treat Adult Patients With Type 2 Diabetes Mellitus | Image: Zydus (Representative)

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as Zydus) on Monday announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for ZITUVIMETTM (Sitagliptin and Metformin hydrochloride) tablets, 50 mg/500 mg and 50 mg/1000 mg, the company announced through an exchange filing.

ZITUVIMET contains active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The approval of ZITUVIMET is based on research, development, regulatory, and manufacturing work performed by Zydus teams. ZITUVIMET has undergone quality testing for Nitrosamines and potential genotoxic impurities as per current USFDA standards. ZITUVIMETTM is compliant with current USFDA standards of Nitrosamines in Sitagliptin containing products.

“The ZITUVIMET approval further builds on our previous approval of ZITUVIOTM (Sitagliptin) and offers an increased accessibility and affordability to healthcare systems with regard to prescription drugs for type II diabetes. The ZITUVIMETTM approval provides an affordable treatment option for healthcare systems to reduce the rate of growth in drug spending and improves the financial sustainability of the healthcare programs,” said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited.

According to IQVIA™ (MAT Aug-2023), U.S. market for DPP-IV inhibitors and their combinations is US$ 10 bn.

Zydus Lifesciences Limited shares

The shares of Zydus Lifesciences Limited on Monday at  9:47 am IST were trading at Rs 587.25, up by 0.41 percent.

RECENT STORIES

Aditya Birla Lifestyle Brands Lists On Stock Exchanges Post Demerger

Aditya Birla Lifestyle Brands Lists On Stock Exchanges Post Demerger

Andhra Pradesh Sets ₹1 Lakh Crore Investment Target In Aerospace & Defence Sector

Andhra Pradesh Sets ₹1 Lakh Crore Investment Target In Aerospace & Defence Sector

Reliance Jio Rolls Out ₹3,599 Annual Plan with 912.5GB Data, 50GB Cloud Storage 

Reliance Jio Rolls Out ₹3,599 Annual Plan with 912.5GB Data, 50GB Cloud Storage 

Ola Electric Shares Hit All-Time Low Of ₹43.20 On BSE After Q4 Loss Doubles To ₹870 Crore

Ola Electric Shares Hit All-Time Low Of ₹43.20 On BSE After Q4 Loss Doubles To ₹870 Crore

Saudi Arabia & Russia Assure Oil Supply To India, Strait Of Hormuz Tensions Create Short-Term Worry

Saudi Arabia & Russia Assure Oil Supply To India, Strait Of Hormuz Tensions Create Short-Term Worry